Repros Therapeutics Inc.
) recently reported second quarter 2012 loss of 21 cents per share,
wider than the Zacks Consensus Estimate of a loss of 17 cents but
narrower than the year-ago loss of 30 cents per share. Lower
year-over-year loss was attributable to a decrease in clinical
development expenses of the male fertility candidate, Androxal.
Repros did not record any revenues (including interest income)
during this quarter, unlike the prior-year period which recorded
revenues of $1000. The decrease in the top line resulted from the
absence of interest income.
During the quarter, research and development (R&D) expenses
decreased 4% year over year to $2.2 million. The decrease was
attributable to lower clinical development expenses on Androxal due
to the completion of a phase II b study in men with secondary
However, the decrease was partially offset by higher clinical
development expenses related to the commencement of a phase II
vaginal study with female reproductive health candidate,
General and administrative (G&A) expenses declined 35% year
over year to $0.9 million. The decrease was primarily due to lower
stock-based compensation expenses.
In July 2012, Repros reported that the Proellex phase II study
for the treatment of uterine fibroids showed consistent efficacy in
three endpoints after 4 months of trial. Repros stated that the
study will complete enrollment by the end of August 2012. The
company expects to report results from the study by the end of 2012
and move to phase III in the first quarter of 2013.
We currently have an Underperform recommendation on Repros. The
stock carries a Zacks #3 Rank (Hold rating) in the short run.
REPROS THERAPEU (RPRX): Free Stock Analysis
To read this article on Zacks.com click here.